AU2008332968B2 - FVIII peptides and their use in tolerising haemophiliacs - Google Patents

FVIII peptides and their use in tolerising haemophiliacs Download PDF

Info

Publication number
AU2008332968B2
AU2008332968B2 AU2008332968A AU2008332968A AU2008332968B2 AU 2008332968 B2 AU2008332968 B2 AU 2008332968B2 AU 2008332968 A AU2008332968 A AU 2008332968A AU 2008332968 A AU2008332968 A AU 2008332968A AU 2008332968 B2 AU2008332968 B2 AU 2008332968B2
Authority
AU
Australia
Prior art keywords
peptide
peptides
fviii
factor viii
haemophilia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008332968A
Other languages
English (en)
Other versions
AU2008332968A1 (en
Inventor
David Wraith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worg Pharmaceuticals Zhejiang Co Ltd
Original Assignee
Worg Pharmaceuticals Zhejiang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worg Pharmaceuticals Zhejiang Co Ltd filed Critical Worg Pharmaceuticals Zhejiang Co Ltd
Publication of AU2008332968A1 publication Critical patent/AU2008332968A1/en
Assigned to APITOPE INTERNATIONAL NV reassignment APITOPE INTERNATIONAL NV Request for Assignment Assignors: APITOPE TECHNOLOGY (BRISTOL) LIMITED
Priority to AU2014200237A priority Critical patent/AU2014200237B2/en
Application granted granted Critical
Publication of AU2008332968B2 publication Critical patent/AU2008332968B2/en
Assigned to Wong Pharmaceuticals (Hangzhou) Co., Ltd. reassignment Wong Pharmaceuticals (Hangzhou) Co., Ltd. Request for Assignment Assignors: APITOPE INTERNATIONAL NV
Assigned to Worg Pharmaceuticals (Zhejiang) Co., Ltd. reassignment Worg Pharmaceuticals (Zhejiang) Co., Ltd. Request to Amend Deed and Register Assignors: Worg Pharmaceuticals (Hangzhou) Co., Ltd.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008332968A 2007-12-04 2008-12-03 FVIII peptides and their use in tolerising haemophiliacs Ceased AU2008332968B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014200237A AU2014200237B2 (en) 2007-12-04 2014-01-15 FVIII peptides and their use in tolerising haemophiliacs

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0723712.6A GB0723712D0 (en) 2007-12-04 2007-12-04 Peptides
GB0723712.6 2007-12-04
PCT/GB2008/003996 WO2009071886A1 (en) 2007-12-04 2008-12-03 Fviii peptides and their use in tolerising haemophiliacs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014200237A Division AU2014200237B2 (en) 2007-12-04 2014-01-15 FVIII peptides and their use in tolerising haemophiliacs

Publications (2)

Publication Number Publication Date
AU2008332968A1 AU2008332968A1 (en) 2009-06-11
AU2008332968B2 true AU2008332968B2 (en) 2014-03-20

Family

ID=38982965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008332968A Ceased AU2008332968B2 (en) 2007-12-04 2008-12-03 FVIII peptides and their use in tolerising haemophiliacs

Country Status (25)

Country Link
US (1) US8445448B2 (cg-RX-API-DMAC7.html)
EP (1) EP2227488B3 (cg-RX-API-DMAC7.html)
JP (2) JP5501245B2 (cg-RX-API-DMAC7.html)
KR (1) KR101519840B1 (cg-RX-API-DMAC7.html)
CN (2) CN103709234B (cg-RX-API-DMAC7.html)
AU (1) AU2008332968B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820143A2 (cg-RX-API-DMAC7.html)
CA (2) CA2707559C (cg-RX-API-DMAC7.html)
CY (1) CY1115168T1 (cg-RX-API-DMAC7.html)
DK (1) DK2227488T6 (cg-RX-API-DMAC7.html)
EA (1) EA019370B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010327A (cg-RX-API-DMAC7.html)
ES (1) ES2458315T7 (cg-RX-API-DMAC7.html)
GB (1) GB0723712D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20140344T4 (cg-RX-API-DMAC7.html)
IL (1) IL205780A (cg-RX-API-DMAC7.html)
MX (1) MX2010006084A (cg-RX-API-DMAC7.html)
MY (1) MY150995A (cg-RX-API-DMAC7.html)
NZ (1) NZ585217A (cg-RX-API-DMAC7.html)
PL (1) PL2227488T6 (cg-RX-API-DMAC7.html)
PT (1) PT2227488E (cg-RX-API-DMAC7.html)
SI (1) SI2227488T1 (cg-RX-API-DMAC7.html)
UA (1) UA101003C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009071886A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002997B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2353347T3 (es) 2000-08-21 2011-03-01 Apitope Technology (Bristol) Limited Péptido.
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
SI2300497T1 (sl) * 2008-06-24 2013-02-28 Octapharma Ag Postopek za äťiĺˇäťenje koagulacijskega faktorja viii
GB0908515D0 (en) * 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
CA2765657A1 (en) * 2009-06-16 2010-12-23 Tokai University Anti-gram-negative bacteria agent
CN104926947A (zh) 2010-10-27 2015-09-23 巴克斯特国际公司 用于免疫耐受性诱导和免疫诊断的fviii肽
CA2863329C (en) 2012-01-12 2023-01-03 Biogen Idec Ma Inc. Methods of reducing immunogenicity against factor viii in individuals undergoing factor viii therapy
EA036483B1 (ru) * 2012-11-12 2020-11-16 Эпитоп Интернэшнл Нв Пептиды, способные индуцировать толерантность к рекомбинантному fviii, содержащая их композиция, их применение и способ лечения гемофилии
GB201314052D0 (en) 2013-08-06 2013-09-18 Apitope Int Nv Peptides
CA3007262A1 (en) 2015-12-03 2017-06-08 Lucas James Thompson Modified chimeric receptors and related compositions and methods
KR20190091292A (ko) 2016-12-02 2019-08-05 바이오버라티브 테라퓨틱스 인크. 응고 인자에 대한 면역 내성 유도 방법
US12077607B2 (en) * 2021-09-23 2024-09-03 University Of Utah Research Foundation Functional and therapeutic effects of PAR4 cleavage by cathepsin G

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5930890A (en) * 1989-06-20 1991-01-08 Scripps Clinic And Research Foundation The phospholipid binding domain of factor viii
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
ES2353347T3 (es) * 2000-08-21 2011-03-01 Apitope Technology (Bristol) Limited Péptido.
HUP0303171A2 (hu) * 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
AU2003232482A1 (en) * 2002-04-18 2003-10-27 Merck Patent Gmbh Modified factor viii
AU2005211725B2 (en) * 2004-02-09 2010-07-15 Human Genome Sciences, Inc. Albumin fusion proteins
WO2006003183A1 (de) 2004-07-02 2006-01-12 Alois Jungbauer Peptide zur blockierung von fviii-inhibitoren
IL229645A0 (en) * 2013-11-26 2014-03-31 Omrix Biopharmaceuticals Ltd A dry bandage containing thrombin and pectin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002060917A2 (en) * 2000-12-01 2002-08-08 Regents Of The University Of Minnesota Method to treat hemophilia

Also Published As

Publication number Publication date
BRPI0820143A2 (pt) 2015-05-12
ES2458315T7 (es) 2015-02-18
NZ585217A (en) 2012-11-30
PT2227488E (pt) 2014-04-21
US20100323966A1 (en) 2010-12-23
SI2227488T1 (sl) 2014-06-30
MX2010006084A (es) 2010-06-23
AU2008332968A1 (en) 2009-06-11
EP2227488B3 (en) 2014-11-19
CY1115168T1 (el) 2016-12-14
ECSP10010327A (es) 2010-09-30
IL205780A0 (en) 2010-11-30
CN101889024A (zh) 2010-11-17
EA019370B1 (ru) 2014-03-31
CN103709234A (zh) 2014-04-09
PL2227488T3 (pl) 2014-07-31
DK2227488T6 (en) 2015-02-16
EP2227488B1 (en) 2014-01-22
IL205780A (en) 2015-06-30
CA3005013A1 (en) 2009-06-11
KR101519840B1 (ko) 2015-05-18
EA201070681A1 (ru) 2010-10-29
HK1144292A1 (en) 2011-02-11
HRP20140344T4 (hr) 2015-07-31
UA101003C2 (uk) 2013-02-25
ES2458315T3 (es) 2014-04-30
CA2707559C (en) 2018-07-03
DK2227488T3 (da) 2014-04-22
CN101889024B (zh) 2014-04-23
JP5501245B2 (ja) 2014-05-21
US8445448B2 (en) 2013-05-21
ZA201002997B (en) 2011-07-27
JP2011505414A (ja) 2011-02-24
HRP20140344T1 (en) 2014-05-09
MY150995A (en) 2014-03-31
PL2227488T6 (pl) 2015-04-30
CN103709234B (zh) 2017-01-18
GB0723712D0 (en) 2008-01-16
WO2009071886A1 (en) 2009-06-11
CA2707559A1 (en) 2009-06-11
KR20100087346A (ko) 2010-08-04
JP6063402B2 (ja) 2017-01-18
EP2227488A1 (en) 2010-09-15
JP2014088440A (ja) 2014-05-15
CA3005013C (en) 2021-11-16

Similar Documents

Publication Publication Date Title
AU2008332968B2 (en) FVIII peptides and their use in tolerising haemophiliacs
AU2010250957B2 (en) FVIII-derived peptides
AU2014200237B2 (en) FVIII peptides and their use in tolerising haemophiliacs
HK1144292B (en) Fviii peptides and their use in tolerising haemophiliacs
HK1172240A (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1172240B (en) Fviii-derived peptides and their use in tolerising haemophiliacs
HK1173358B (en) Fviii-derived peptides

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: APITOPE INTERNATIONAL NV

Free format text: FORMER APPLICANT(S): APITOPE TECHNOLOGY (BRISTOL) LIMITED

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: WONG PHARMACEUTICALS (HANGZHOU) CO., LTD.

Free format text: FORMER OWNER(S): APITOPE INTERNATIONAL NV

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE PATENTEE NAME TO READ WORG PHARMACEUTICALS (HANGZHOU) CO., LTD.

HB Alteration of name in register

Owner name: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.

Free format text: FORMER NAME(S): WORG PHARMACEUTICALS (HANGZHOU) CO., LTD.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired